Akorn AKRX sold its branded drug unit for $41 million and saw its shares gain nearly four percent Friday morning.
The unit, ECR Pharmaceuticals, went to Valeant Pharmaceuticals VRX for a combination of $41 million cash and debt, Akorn said.
ECR was part of Akorn's $640 million acquisition of Hi-Tech Pharmacal about a year ago.
Chief Executive Raj Rai said the unit is a "solid platform" but not "a strategic fit" with Akorn's model of of focusing on niche dosage forms.
Akorn, which posted first-quarter revenue of $90.6 million, will update 2014 guidance in an earnings conference call in August.
Akorn shares traded recently at $29, up 3.45 percent.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.